Mr. Mark Upsdell reports

RAPID DOSE ANNOUNCES PAYMENT IN SHARES FOR QUARTERLY INTEREST ON SECURED DEBT

Rapid Dose Therapeutics Corp. -- as contemplated in the secured convertible notes previously issued on its private placement financing, and consistent with prior quarters -- intends to issue common shares in satisfaction of the accrued interest payable on June 30, 2025, under the terms of the notes. The company expects to issue the common shares no later than July 15, 2025.

The financing was an offering of units at a price of $1.00 per unit. Each unit consisted of $1.00 principal amount of notes and five common share purchase warrants of the company. The company closed all four tranches of the financing in 2023, issuing an aggregate of $3,134,445 principal amount of notes and 15,672,225 warrants.

The notes have a maturity date of Nov. 30, 2025, and bear interest from their date of issue at 12.0 per cent per annum, calculated monthly, accrued, added to principal and payable quarterly in arrears in common shares at a price per share equal to the closing market price of the common shares on the Canadian Securities Exchange (CSE) on the last trading day of each calendar quarter.

Therefore, in accordance with the terms of the notes, the company intends to issue a total of 506,878 common shares to the holders of the notes at a deemed issue price of 18.5 cents per common share, being the closing market price of the common shares on the CSE on June 30, 2025, in satisfaction of the aggregate of $93,775.72 of accrued interest owing on the notes.

All common shares issued as payment for accrued interest will be subject to a hold period expiring four months and one day from the date of issue of the common shares.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient.

We seek Safe Harbor.